JBCPL gets trademark assignment of heart failure drug Azmarda from Novartis - Video
|
Overview
JB Chemicals and Pharmaceuticals (JBCPL) has recently announced that the company has approved the assignment of trademark for Azmarda indicated for heart failure patients with reduced ejection fraction (HFrEF) from Novartis AG, Switzerland for India.
Azmarda is a brand of sacubitril/valsartan, the first-in-class angiotensin receptor neprilysin inhibitor (ARNI) presently approved for the treatment of heart failure with reduced ejection fraction (HFrEF).
For more information, check out the full story on the link below:
JBCPL Gets Trademark Assignment Of HF Drug Azmarda From Novartis For Rs 246 Crores
Speakers
Roshni Dhar, a Mass com graduate with a soft corner for health happenings, joined Medical Dialogues as a news anchor in 2021. Inspired by her mother who is a gynaecologist, she likes to keep herself and the world updated on the occurring in the medical field. She covers various aspects of health news for MDTV at Medical Dialogues. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
